Recent Quotes
My Watchlist
Indicators
Local Stocks
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Graphite Bio, Inc.

Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
LENZ Therapeutics and Graphite Bio Announce Merger Agreement
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Departure of Chief Financial Officer
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Jefferies Healthcare Conference
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Upcoming Investor Conferences
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Upcoming Investor Conferences
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
Tickers GRPH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.